GBA's "2021 Stock Phantasma"

Discussion in 'Stocks' started by stonedinvestor, Jan 1, 2021.

  1. Arnie

    Arnie

    What dumb luck. I have 10 F Feb 5 $13 C from .12

    I figured they would expire worthless LOL
     
    #1091     Feb 1, 2021
  2.  
    #1092     Feb 1, 2021
  3. VAN NOW ON EGHT!~

    LAST CALL FOR ALCOHOL!!!!

    8x8, Inc. (EGHT) This should rip this afternoon-!
    NYSE - Nasdaq Real Time Price. Currency in USD

    35.54+0.29 (+0.82%)
    As of 1:27PM EST.
     
    #1093     Feb 1, 2021
  4. Adamas Pharmaceuticals trading halted, news pending
     
    #1094     Feb 1, 2021
  5. Adamas Pharmaceuticals, Inc. (ADMS)
    NasdaqGS - NasdaqGS Real Time Price. Currency in USD

    6.73+0.82 (+13.87%)
    As of 12:59PM EST.<-------- That was long ago!!! What up!!!
     
    #1095     Feb 1, 2021
  6. OMG WE JUST REALLY HELPED PEOPLE WITH PARKENSENS!!!!

    WHERE IS MY GUMMY CREW!!!!! THIS CAN'T BE BAD NEWS!

    [​IMG]
    Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
    February 1, 2021, 2:07 PM·7 min read
    [​IMG]

    - GOCOVRI is now the first and only medication approved to treat OFF and dyskinesia motor complications -

    - Adamas to host webcast conference call today at 4:30 pm ET/1:30 pm PT -

    Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine) extended release capsules, gaining a second indication for the product. GOCOVRI is now approved as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes, in addition to its indication for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

    "The approval of a second indication for GOCOVRI is a major milestone for patients with Parkinson’s who experience motor complications in their daily lives. GOCOVRI is now the first and only medication approved to treat both OFF and dyskinesia motor complications in Parkinson’s disease,"
     
    #1096     Feb 1, 2021
  7.  
    #1097     Feb 1, 2021
  8. mac

    mac

    Nice entry Stoney...perfect timing. As soon as I pulled it up it was halted.

    Should run nice once it resumes.!
     
    #1098     Feb 1, 2021
  9. I think so with that huge price target out there & a CC at 4:30-- Robin Hood has now been notified.

    Tomorrow should be a sea of other upgrades... this is great news! Parkensens is no fun.
     
    #1099     Feb 1, 2021
  10. Major volume! Over 1 mil shares hot! Small float 5% short....
    ADMS-
    Volume 1,470,631 vs Avg. Volume 250,496

    and they can't get her open;)...
     
    #1100     Feb 1, 2021